Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: tyrosinase peptide Clear all

Conditions: Melanoma
Interventions: Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Melanoma (Skin)
Interventions: Autologous dendritic cell-adenovirus CCL21 vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions: tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: aldesleukin, incomplete Freund's adjuvant, recombinant tyrosinase-related protein-2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Baylor Health Care System; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Montanide ISA 51; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI); Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
Interventions: RO7293583, Tocilizumab, Obinutuzumab, Adalimumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy; Biological · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: ipilimumab, Tyrosinase/gp100/MART-1 Peptides; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 32
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more

Conditions: Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions: Peptide vaccine, GM-CSF, PF3512676; Biological
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: Synchrotope TA2M; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin)
Interventions: OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein, tyrosinase peptide; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, tyrosinase peptide; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions: gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 2
States / cities: Duarte, California • Los Angeles, California

Search by objective public record fields.

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Dendritic Cell Vaccination During Lymphoid Reconstruction

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma